Study of HCB301 for advanced solid tumors and Hodgkin lymphoma
Part of Blood & lymphatic, Bones, joints & muscles, Cancer, Genetic & congenital, Immune system & allergy clinical trials.
This trial tests a new drug called HCB301, which targets proteins that help cancer hide from the immune system. It is for people with advanced solid tumors or classical Hodgkin lymphoma who have tried other treatments without success.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an advanced solid tumor or classical Hodgkin lymphoma that hasn't responded to standard treatments or has come back.
- You are 18 years or older.
- You are able to do daily activities with little or no help (ECOG 0 or 1).
- You can provide a tumor sample from a biopsy or surgery.
- You have not had certain other treatments or major surgeries in the last few weeks.
- You do not have untreated brain tumors, serious heart issues, active infections (like hepatitis, HIV), or a history of bleeding problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests HCB101, an immune-targeting drug, to see if it is safe and can shrink certain solid tumors or non-Hodgkin lymphoma. It may help people whose cancer has returned or stopped responding to standard treatments.
This study tests a new drug called HC006 for advanced solid tumors that no longer respond to standard treatments. It aims to find a safe dose and see if it helps shrink tumors.
This trial is testing a new drug (HC010) for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe, how it works in the body, and whether it can shrink tumors.
This Phase 1 trial tests HS-10386 (an experimental treatment) in people with advanced solid tumors that can’t be cured with standard options. The goal is to find a safe dose and see how the cancer responds.
This Phase 1/2 trial tests the safety and early effectiveness of HH2853 in people whose cancer has come back or did not respond to prior treatment. It may help shrink tumors and guide future treatment for specific cancer types and genetic changes.
This early-phase study tests whether HB0036 is safe and can work in people with advanced solid tumors (cancers) that have come back or spread and did not respond to standard treatments. You may be considered especially if your tumor matches certain tumor types and biomarker results.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.